n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid in 3 studies
| Studies (n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid) | Trials (n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid) | Recent Studies (post-2010) (n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid) | Studies (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) | Trials (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) | Recent Studies (post-2010) (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) |
|---|---|---|---|---|---|
| 40 | 0 | 7 | 792 | 16 | 476 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brechbiel, MW; Chappell, LL; Dadachova, E; Garmestani, K; Ma, D; Milenic, DE; Schlom, J; Yordanov, A | 1 |
| Abrahmsén, L; Ahlgren, S; Brechbiel, MW; Hjertman, M; Orlova, A; Sandström, M; Sjöberg, A; Tolmachev, V; Wållberg, H; Xu, H | 1 |
| Bigner, DD; Hens, M; Vaidyanathan, G; Zalutsky, MR; Zhao, XG | 1 |
3 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
| Article | Year |
|---|---|
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Topics: Adenocarcinoma; Aniline Compounds; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Isothiocyanates; Lutetium; Mice; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Whole-Body Counting; Xenograft Model Antitumor Assays | 2002 |
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Topics: Animals; Antibodies; Binding Sites; Cell Line, Tumor; Chelating Agents; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Isothiocyanates; Maleimides; Mice; Pentetic Acid; Receptor, ErbB-2; Recombinant Fusion Proteins; Staining and Labeling; Substrate Specificity; Tissue Distribution | 2008 |
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; ErbB Receptors; Flow Cytometry; Glioma; Heterocyclic Compounds, 1-Ring; Humans; Isothiocyanates; Lutetium; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Stereoisomerism; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |